Thorough QT/QTc trial of RPC 1063 in volunteers.

Trial Profile

Thorough QT/QTc trial of RPC 1063 in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2014

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Multiple sclerosis; Ulcerative colitis
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Dec 2013 New trial record
    • 05 Jun 2013 Primary endpoint `No significant difference between RPC 1063 and placebo in prolongation of corrected QT interval' has been met, according to a Receptos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top